Page 80 - Eceptor News Today

Researchers assessed the effect of fenofibrate on acute COVID-19.

Parkinson's disease affects 3% of population over 65 years old, and the average age of onset is 60. Regarding juvenile Parkinson, which represents the of all Parkison's cases, the disease begins before 40 years old.

Researchers at Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine have shown that a protein complex that governs gene expression (called CoREST) sometimes gets rewired during breast cancer to help estrogen receptor positive (ER+) tumors resist endocrine therapies and become more aggressive.

In a recent study posed to the bioRxiv* preprint server, researchers at Virginia Tech University investigated wildlife exposure to SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2).

There is a need for new, effective treatments for mental illnesses like depression and anxiety. Researchers are expanding the field's therapeutic toolbox by investigating the antidepressant and anxiolytic properties of drugs such as psilocybin and cannabis.

Ramping up medication doses quickly after being hospitalized for acute heart failure resulted in a lower risk of dying or being readmitted for heart failure within the first six months after discharge, compared to usual care, according to a featured science research presentation today at the American Heart Association's Scientific Sessions 2022.

Researchers recently measured the neutralizing antibody titers against the wild-type strain of SARS-CoV-2 and the SARS-CoV-2 Omicron subvariants in healthcare workers fully vaccinated with three doses of the Comirnaty vaccine who experienced breakthrough Omicron infections.

Patients with nasopharyngeal cancer are often treated with drugs that activate their immune system against the tumor.

The Native Antigen Company (part of LGC Clinical Diagnostics), one of the world’s leading suppliers of reagents that enables research into vaccines and diagnostics for emerging and endemic infectious diseases, today announced the commercial launch of its latest SARS-CoV-2 antigens for the newly designated Omicron BA.5 variant.

A new study describes a system by which gut-brain pathways coordinate with brain circuits to initiate nausea and vomiting.